TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01751503

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interosseous route of TPTT
Description: Anterior transposition of Posterior tibialis tendon (PTT) is the gold standard for surgical restoration of functional dorsiflexion of a permanently paralyzed foot. Two methods of rerouting the posterior tibialis tendon have been reported, one through the interosseous membrane i.e. Interosseous route and second subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extra membranous route of TPTT
Description: Rerouting the posterior tibialis tendon subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route (
Study: NCT04582552

Intervention type: DRUG
Intervention: PARP inhibitors
Description: Ovarian cancer patients with PARP inhibitors according to the NCCN guideline and their instructions.
Study: NCT01844258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified technique
Description: Peripheral 1-1.5 mm curvilinear capsulorhexis of anterior capsule
Study: NCT02826174

Intervention type: PROCEDURE
Group type: OTHER
Intervention: open-sky PKP under retrobulbar anesthesia
Description: an open-sky corneal transplantation under retrobulbar anesthesia

Intervention type: PROCEDURE
Group type: OTHER
Intervention: open-sky PKP under retrobulbar anesthesia
Description: an open-sky corneal transplantation under retrobulbar anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open-sky PKP under retrobulbar anesthesia
Description: an open-sky corneal transplantation under retrobulbar anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Rejection Agents
Description: Anti-Rejection Agents for both groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Rejection Agents
Description: Anti-Rejection Agents for both groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Inflammatory Agents
Description: Anti-Inflammatory Agents for both groups
Study: NCT01844258

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional technique
Description: Central 5-6 mm curvilinear capsulorhexis of anterior capsule
Study: NCT03254901

Intervention type: OTHER
Intervention: Screening test by Oraquick test
Description: The OraQuick assay uses an indirect immunoassay method to detect hepatitis C antibodies in oral fluid or blood
Study: NCT03621137

Intervention type: OTHER
Intervention: No study-specific intervention
Description: Treatment of atopic eczema with phototherapy or systemic immunomodulating therapy according to usual clinical practice
Study: NCT03071796

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multivitamin supplement
Description: supplement includes 97 natural extracts

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: liquids with similar appearance and taste like multivitamin supplement for 12 weeks
Study: NCT03271736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepping-in-place exercise with external auditory cues
Description: The stepping-in-place exercise includes 10-session training. In each session, subjects are asked for stepping for 50 steps. In auditory cued condition, the cued frequency is set at 110% of the usual walking cadence. While in non-cued condition, we ask the subjects to step according to their own internal rhythm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepping-in-place exercise with external auditory cues
Description: The stepping-in-place exercise includes 10-session training. In each session, subjects are asked for stepping for 50 steps. In auditory cued condition, the cued frequency is set at 110% of the usual walking cadence. While in non-cued condition, we ask the subjects to step according to their own internal rhythm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: TMS is used to assess the cortical excitability of the motor cortex. The stimulation intensity is set at 130% of the motor threshold in single-pulse condition. In paired-pulse condition, the first stimulus is set at 80% of the motor threshold and the second stimulus is set at 130% of the motor threshold.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: TMS is used to assess the cortical excitability of the motor cortex. The stimulation intensity is set at 130% of the motor threshold in single-pulse condition. In paired-pulse condition, the first stimulus is set at 80% of the motor threshold and the second stimulus is set at 130% of the motor threshold.
Study: NCT03087201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nabiximols
Description: starting dose (1 puff): 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD), maximum dose (12 puffs): 32.4 mg THC/30 mg CBD, no target dose is defined~Duration of treatment: 13 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: analogous to experimental intervention
Study: NCT02710604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CMX157
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CMX157
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CMX157
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CMX157
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CMX157
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300mg tablet
Study: NCT00322335

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemophilus influenzae type b- and meningococcal (vaccine)
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (group HibMenC) and as booster dose at 14 months of age (groups HibMenC and group NeisPoo).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b- and meningococcal (vaccine)
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (group HibMenC) and as booster dose at 14 months of age (groups HibMenC and group NeisPoo).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™ penta
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ hexa
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and/or 6 months of age (groups NeisPoo and MenCCRM) and/or as booster dose at 14 months of age (group MenCCRM).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ hexa
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and/or 6 months of age (groups NeisPoo and MenCCRM) and/or as booster dose at 14 months of age (group MenCCRM).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Intramuscular injection into the thigh as a birth dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NeisVac-C™
Description: Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ IPV/HIB
Description: Intramuscular injection into the thigh as primary vaccination at 4 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec™
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
Study: NCT01686243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: epidural needle placement with echogenic 17G Tuohy needles (Pajunk TuohySono)
Description: Anesthesiologist will place epidural with aid of ultrasound and placement with echogenic 17G Tuohy needles (Pajunk TuohySono)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard epidural placement
Description: Anesthesiologist will place epidural within standard practice, with standard needles.
Study: NCT00502697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Nurse Home Visits
Description: Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic care. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional prenatal/postpartum care
Description: Women in this group received conventional prenatal care and postpartum clinic care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional prenatal/postpartum care
Description: Women in this group received conventional prenatal care and postpartum clinic care.
Study: NCT02307552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UreScan
Description: The TUUS Foley/catheter will be inserted into the urethra via the ultrasound visualization onto the apex prostate, and the ultrasound extended through the urethra until the bladder neck and stopped. This is recorded twice automatically, and this should take 5-10 minutes for completion, and the prostate ultrasound data stored in memory. The ultrasound/subject interaction is now complete, and the study should add 30-60 minutes to the preoperative visit. No local or general anesthesia is used. The subject will be given 500 mg of Ciprofloxacin as a preventative measure against a urinary tract infection.
Study: NCT03459196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERMOCOOL SMARTTOUCH SF-5D Catheter
Description: radiofrequence ablation with THERMOCOOL SMARTTOUCH® SF-5D catheter used in combination with the nMARQ™ Multi-Channel RF Generator with TGA mode
Study: NCT02177240

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GlideScope® intubation with Flex-it® stylet
Description: GlideScope® intubation with Flex-it® stylet of a simulated difficult airway

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GlideScope® intubation with GRS® stylet
Description: GlideScope® intubation with GRS® stylet of a simulated difficult airway
Study: NCT02826174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Inflammatory Agents
Description: Anti-Inflammatory Agents for both groups
Study: NCT03901352

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirogabalin
Description: Mirogabalin tablets for oral administration
Study: NCT01414062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cocinar Para Su Salud Program
Description: A series of 9 Cocinar Para Su Salud intervention sessions held over a 12-week period. The 12-week intervention period will be divided into 3 groups: motivation, action, and environment. Each topic will use a nutrition roundtable, food shopping field trip, and a cooking class to teach pertinent points, in order to enable participants to progress from the precontemplation, contemplation, and preparation stages of change to the action and maintenance stages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written dietary recommendations
Description: Standard of care: one on one meetings with study staff to receive compiled written information on dietary recommendations for breast cancer survivors produced by the New York City (NYC)-based not-for-profit, God's Love We Deliver
Study: NCT01726426

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Each capsule Probiotics (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Each capsule Probiotics (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Each capsule Probiotics (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
Study: NCT03323944

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART-meso cells
Description: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART-meso cells
Description: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART-meso cells
Description: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART-meso cells
Description: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART-meso cells
Description: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells.
Study: NCT02835664

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside (Niagen)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nicotinamide Riboside (Niagen)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01577082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF1535 200/6 µg
Description: CHF 1535 (BDP/FF) 800/24 µg daily during 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDP 100 µg
Description: Beclomethasone Dipropionate 800µg daily during 12 weeks
Study: NCT01901393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Study: NCT02860026

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Marketed cow's milk-based infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cow's milk-based infant formula with added nutrients
Study: NCT02230332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01600755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iltamiocel
Description: Single intrasphincteric injection of iltamiocel at a dose of 250 x 10\^6 cells
Study: NCT01815372

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single penetration dual injection (SPEDI) block technique to block the sciatic and the saphenous nerve with one needle penetration of the skin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The classical popliteal sciatic nerve block combined with the mid-femoral saphenous nerve block
Study: NCT03058159

Intervention type: OTHER
Group type: OTHER
Intervention: fMRI
Description: fMRI scans will be acquired before and after a 40 min nap slot in the afternoon. Functional connectivity between brain region will be assessed analyzing the scans with the CONN toolbox of the Statistical Parametric Mapping (SPM) software.

Intervention type: OTHER
Group type: OTHER
Intervention: fMRI
Description: fMRI scans will be acquired before and after a 40 min nap slot in the afternoon. Functional connectivity between brain region will be assessed analyzing the scans with the CONN toolbox of the Statistical Parametric Mapping (SPM) software.
Study: NCT00536991

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given PO
Study: NCT04143568

Intervention type: OTHER
Intervention: Observation
Description: Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease

Intervention type: OTHER
Intervention: Observation
Description: Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
Study: NCT00902265

Intervention type: DRUG
Intervention: desmopressin
Description: desmopressin (Nocturin®) 0.1 mg tablet per day for 12 weeks
Study: NCT01652807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha Yoga
Description: The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching. Each participant will be given a yoga studio scan card valid for two months, and, like all yoga studio members, they will be required to scan their card prior to their yoga class.
Study: NCT01984970

Intervention type: DEVICE
Intervention: videolaryngoscope
Description: McGrath Series 5 videolaryngoscope is one kind of portable videolaryngoscopes, which has been usde in both unexpected and anticipated difficult intubation.
Study: NCT04279483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7-11
Description: Assigned to make a small (\~$3.00) purchase from any 7-11 store(s) using a study-provided debit card during each retail environment visit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CVS
Description: Assigned to make a small (\~$3.00) purchase from any CVS store(s) using a study-provided debit card during each retail environment visit.
Study: NCT03734120

Intervention type: OTHER
Intervention: cryopreservation
Description: Samples were frozen with a programmable freezing unit. Each semen sample was divided into two aliquots. One aliquot was plunged into liquid nitrogen and the other was stored in dry-phase nitrogen for 3 or 6 month. Thawing was performed at room temperature
Study: NCT04196283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous (IV) infusion
Study: NCT01882127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoid Acid(ATRA)
Description: patients in ATRA\&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients in High dose-DEX treatment group take dexamethasone( orally , 40mg daily for 4 days),patients in ATRA\&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients in High dose-DEX treatment group take dexamethasone( orally , 40mg daily for 4 days),patients in ATRA\&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
Study: NCT04453475

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training session adressing information and health literacy
Description: The training sessions are provided online and as alternative to face-to-face treatments which cannot be provided as before due to the safety regulations relating to Covid-19

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training session adressing information and health literacy
Description: The training sessions are provided online and as alternative to face-to-face treatments which cannot be provided as before due to the safety regulations relating to Covid-19

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training session adressing information and health literacy
Description: The training sessions are provided online and as alternative to face-to-face treatments which cannot be provided as before due to the safety regulations relating to Covid-19

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training session adressing information and health literacy
Description: The training sessions are provided online and as alternative to face-to-face treatments which cannot be provided as before due to the safety regulations relating to Covid-19
Study: NCT01554696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral
Study: NCT03568422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-402257
Description: Orally taken on intermittent schedule (days 1, 2, 8, 9, 15 \& 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 IV days 1, 8 \& 15 every 28 days
Study: NCT04146103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novex
Description: Novex® made of Pumpkin Seed Extract 550mg, Soy Germ Isoflavonoids 50 mg and Cranberry 50mg. The dose is 2 tablets/day taken orally.
Study: NCT01554696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral
Study: NCT01527552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days